RAINBOW · NSE
Rainbow Childrens Medicare Limited
₹1,454.7
-1.27% (-₹18.7)
Prev. close
₹1,473.4
Volume
99,805
Delivery %
53.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Rainbow Childrens Medicare Limited
Rainbow Children's Medicare Limited operates a multi-specialty pediatric, obstetrics, and gynecology hospital chain in India. The company offers medical and healthcare services to children and women. It also provides pediatric services under brand Rainbow Children's Hospital which include newborn and pediatric intensive care; pediatric multi-specialty services; and pediatric quaternary care, such as multi-organ transplantation. In addition, the company offers women care services under Birthright brand that comprise perinatal care services, such as routine and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility support, and a range of gynecology treatments, as well as operates private pediatric DNB (Diplomate of National Board) training program offering postgraduate and fellowship opportunities to train future healthcare professionals. Rainbow Children's Medicare Limited was incorporated in 1998 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Abrarali Dalal
Headquarters
Hyderabad
Employees
4,724
Website
rainbowhospitals.inExchange
View on NSE ↗Key stats
Market cap
₹14,757.95 Cr
P/E ratio (TTM)
51.7
Dividend yield
0.24%
EPS (TTM)
₹28.14
Beta (1Y · daily vs NIFTY 50)
0.55
Beta (5Y · monthly vs NIFTY 50)
0.78
Shares float
4.87 Cr
EPS · quarter ended Jun 2026
₹5.97
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹973.76 Cr | ₹1,173.57 Cr | ₹1,296.90 Cr | ₹1,515.87 Cr | ₹1,703.08 Cr | |
| EBITDA | — | ₹323.81 Cr | ₹427.24 Cr | ₹465.95 Cr | ₹540.90 Cr | ₹586.42 Cr |
| — | ₹138.27 Cr | ₹210.83 Cr | ₹217.00 Cr | ₹243.42 Cr | ₹278.32 Cr | |
| Diluted EPS | — | ₹14.75 | ₹20.89 | ₹21.38 | ₹23.84 | ₹27.41 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,081.27 Cr | ₹1,295.75 Cr | ₹1,776.30 Cr | ₹2,170.40 Cr | ₹2,376.99 Cr | ₹2,774.84 Cr | |
| ₹518.47 Cr | ₹566.55 Cr | ₹570.32 Cr | ₹765.31 Cr | ₹763.58 Cr | ₹890.98 Cr | |
| Stockholders' equity | ₹446.36 Cr | ₹602.80 Cr | ₹1,059.91 Cr | ₹1,258.93 Cr | ₹1,468.19 Cr | ₹1,648.07 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹223.73 Cr | ₹327.23 Cr | ₹321.40 Cr | ₹395.66 Cr | ₹419.66 Cr | |
| Investing cash flow | — | ₹-175.35 Cr | ₹-465.20 Cr | ₹-226.47 Cr | ₹-267.80 Cr | ₹-258.65 Cr |
| — | ₹-44.06 Cr | ₹143.41 Cr | ₹-101.78 Cr | ₹-117.72 Cr | ₹-147.37 Cr | |
| Capital expenditure | — | ₹-62.23 Cr | ₹-141.30 Cr | ₹-353.58 Cr | ₹-145.67 Cr | ₹-216.46 Cr |
| End cash position | ₹5.66 Cr | ₹9.98 Cr | ₹16.97 Cr | ₹10.12 Cr | ₹20.26 Cr | ₹33.89 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | May 22–Mar 24(9Q) | Jun 24 | Sep 24–Sep 25(5Q) | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|
| Promoter | 49.83% | 49.88% | 49.85% | 49.84% | 49.84% | 49.84% |
| Public | 50.17% | 50.12% | 50.15% | 50.12% | 50.04% | 49.98% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.04% | 0.12% | 0.18% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Rainbow Childrens Medicare Limited | ₹14,783.31 Cr | ₹1,473.4 | 51.9 | 8.97 | 16.9% | 0.54 | +12.2% | +1.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Rainbow Children’s Medicare: Completes 64% Acquisition in Medical Care LLP
InvestyWise · 1 month ago